study on [F-18] FDG and [F-18] FLT in the assessment of malignant tumors

study on [F-18] FDG and [F-18] FLT in the assessment of malignant tumors - study on [F-18] FDG and [F-18 FLT in the assessment of malignant tumors

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029524

Enrollment

120

Registered

2019-04-01

Start date

2017-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant tumors

Interventions

FLT-PET/CT

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. [F-18] FDG PET/CT is covered by insurance 2. patients who are 20 years of age or over 3. written informed consent has been obtained

Exclusion criteria

Exclusion criteria: 1. patients with blood sugar level over 200mg/dl when they take [F-18] FDG PET/CT 2. patients who are pregnant or have high possibility of pregnancy 3. patients who are unable to give an appropriate consent in terms of mental and legal point of view

Design outcomes

Primary

Measure	Time frame
to show improved detectability of primary malignant tumors and their metastases or reccurrences, and the efficacy in the assessment of treatment response and prognosis using [F-18] FLT PET/CT.	—

Countries

Japan

Contacts

Public ContactJunichi Tsuchiya

Medical Hospital Tokyo Medical and Dental University Department of Diagnostic Radiology

tcymrad@tmd.ac.jp03-5803-5311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026